ARS Pharmaceuticals (SPRY) Long-Term Deferred Tax (2023 - 2025)
ARS Pharmaceuticals (SPRY) posted Long-Term Deferred Tax of $73.4 million for Q4 2025, up 99.13% sequentially from $36.9 million in Q4 2024, and up 99.13% YoY from $36.9 million in Q4 2024.
ARS Pharmaceuticals (SPRY) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
ARS Pharmaceuticals has reported Long-Term Deferred Tax for 3 years, with the latest figure at $73.4 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 99.13% year-over-year to $73.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $73.4 million (up 99.13% YoY) and the FY2025 annual result came in at $73.4 million, up 99.13% from the prior year.
- Long-Term Deferred Tax climbed to $73.4 million in Q4 2025 per SPRY's latest filing, from $36.9 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $73.4 million in Q4 2025 and troughed at $29.0 million in Q4 2023.
- A 3-year average of $46.4 million and a median of $36.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax advanced 26.92% in 2024, then surged 99.13% in 2025.
- Over 3 years, Long-Term Deferred Tax stood at $29.0 million in 2023, then advanced by 26.92% to $36.9 million in 2024, then soared by 99.13% to $73.4 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $73.4 million, $36.9 million, and $29.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73.41 Mn |
| Dec 31, 2024 | 36.86 Mn |
| Dec 31, 2023 | 29.04 Mn |